$SLGN

SLGN Maintained by UBS -- Price Target Lowered to $38

UBS analyst Anoja Shah maintained a Neutral rating on Silgan Holdings (SLGN) but lowered the price target from $47 to $38, citing potential challenges. GuruFocus values SLGN at $52, suggesting a 32.7% undervaluation. The company has a GF Score of 81/100, with strengths in profitability and valuation but weaknesses in financial strength.

Original reporting
Published Oct 5, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SLGN
Bearish
medium confidence
Mentioned
$SLGN
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SLGNBearishMed
01

Why it matters

The target reduction may trigger short‑term sell‑offs, but the stock remains undervalued per GuruFocus metrics.

02

Market read

Analyst rating change is the primary new information, offering a modest trading signal for SLGN.

03

What to watch

Potential raw‑material cost volatility and demand shifts were not quantified in the rating change.

Relevance 6/10Novelty 6/10Timing: intraday today

Background

Silgan Holdings manufactures rigid packaging for consumer goods; UBS analysts adjusted valuation amid raw‑material cost concerns.

Company-level read

Ticker impact

$SLGNBearishMedium confidence
Context

UBS lowered its price target for Silgan Holdings to $38 from $47, maintaining a neutral rating.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

Analyst downgrade with a 19% target reduction signals weaker outlook; no new catalyst beyond the rating change.

Market effects

Packaging sector may see modest re‑rating pressure as peers are compared to Silgan's outlook.

U.S. consumer‑cyclical segment could see slight bearish tilt.

Limited to investors tracking U.S. packaging stocks.

Counterpoint

Some investors may view the lower target as an entry point given the stock's current undervaluation relative to its GF value.

Key entities

  • Silgan Holdings Inc

    U.S. packaging manufacturer (ticker SLGN).

  • UBS

    Provided the rating update and price target change.

Related articles

$AVYMed

Q2 Earnings Review: Industrial Packaging Stocks Led by Avery Dennison (NYSE:AVY)

Packaging Corporation of America (PCA) reported Q2 revenue of $2.49B, up 14.7% YoY, but missed EPS estimates. International Paper (IP) reported $6.00B revenue, down 11.3% YoY, missing expectations. Silgan Holdings (SLGN) reported $1.64B revenue, up 6.8% YoY, beating estimates. PCA and SLGN stocks are up 1.9% and down 19.7% since reporting, respectively. IP stock is down 18.1% since reporting.

$SLGNMed

Why Silgan Holdings (SLGN) Stock Is Up Today

Silgan Holdings (NYSE:SLGN) shares rose 3.6% to close at $42.15 after RBC Capital Markets upgraded the stock to “Outperform” from “Sector Perform” and raised its price target to $58. RBC cited positive momentum in the Dispensing and Specialty Closures segment, which accounts for 42% of fiscal 2025 sales and about half of EBIT.

$SLGNMed

Why Silgan Holdings (SLGN) Stock Is Up Today

Silgan Holdings (NYSE: SLGN) shares rose 3.6% to $42.15 after RBC Capital Markets upgraded the stock to “Outperform” from “Sector Perform” and raised its price target to $58. RBC cited positive momentum in the Dispensing and Specialty Closures segment, which accounts for 42% of fiscal 2025 sales and about half of EBIT.

$SLGNMed

Silgan Holdings Inc. Q2 2026 Earnings Call Summary

Strategic Performance Drivers Management attributed Q2 performance to strong execution in high-value segments like fine fragrance and wet pet food, which helped offset geopolitical and inflationary headwinds. Dispensing and Specialty Closures (DSC) faced a 15% volume decline in Brazil due to inflationary market conditions, though management views this as a temporary market dynamic rather than a loss of share.

$SLGNMed

Silgan Q2 Earnings Call Highlights

Fabry said the combination of Brazil volume weakness and less favorable mix reduced second-quarter results by about $5 million. Despite that impact, adjusted EBIT in the segment was comparable with the prior year as favorable price over cost offset the volume and mix pressure. Greenlee highlighted continued strong growth in fine-fragrance dispensing products, particularly in Europe.